Inhaled Antibiotics Market Report 2026

Inhaled Antibiotics Market Overview

• Inhaled Antibiotics market size has reached to $1.66 billion in 2025 • Expected to grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Hospital Demand Is A Catalyst For Growth In The Inhaled Antibiotics Market • Market Trend: Increasing Focus On Product Innovations To Provide Reliable Services To Their Customers • North America was the largest region in 2025.

What Is Covered Under Inhaled Antibiotics Market?

Inhaled antibiotics refer to drugs that act as medication for respiratory-related problems. Inhaled antibiotics have enhanced survival and have been used to improve lung function, delay deterioration in lung function, extend time between exacerbations, and improve quality of life. The main types of inhaled antibiotics are aerosol or metered dose inhalers, dry powder formulations, sprays and others. A metered-dose inhaler, or MDI, is a device that is frequently used to provide inhaled respiratory drugs. These are used in various applications such as pneumonia, asthma, bronchitis and others, which are used by hospitals, and others.

What Is The Inhaled Antibiotics Market Growth Forecast?

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing antibiotic resistance, growth in chronic respiratory disease population, advancements in inhalation drug delivery devices, expanding access to respiratory care in emerging markets, pipeline development of novel inhaled antibiotics. Major trends in the forecast period include expansion of inhaled antibiotics for cystic fibrosis and chronic respiratory infections, growing adoption of dry powder inhaled antibiotic formulations, increased focus on reducing systemic side effects through targeted pulmonary delivery, rising hospital use of nebulized antibiotics for severe infections, development of broad-spectrum inhaled antibiotics for drug-resistant pathogens.

Global Inhaled Antibiotics Market Segmentation

1) By Product Type: Aerosol Or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types 2) By Application: Pneumonia, Bronchitis, Other Applications 3) By End-User: Hospitals, Other End Users Subsegments: 1) By Aerosol Or Metered Dose Inhaler: Levofloxacin Inhalation Solution, Tobramycin Inhalation Solution, Aztreonam Inhalation Solution 2) By Dry Powder Formulation: Dry Powder Tobramycin, Dry Powder Colistin 3) By Spray: Antibiotic Nasal Sprays, Inhaled Antibiotic Solutions 4) By Other Types: Nebulized Antibiotics, Intranasal Antibiotics

What Is The Driver Of The Inhaled Antibiotics Market?

The increasing demand in hospitals is expected to propel the growth of the inhaled antibiotics market going forward. Hospitals are healthcare institutions or facilities designed to provide medical treatment, care, and services to individuals who are sick or injured. Inhaled antibiotics are used in the hospital setting, particularly in the treatment of respiratory infections, to minimize the impact on the gut microbiota, to customize treatment plans, to improve patient compliance, and to reduce hospitalization rates. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the increasing demand in hospitals is driving the growth of the inhaled antibiotics industry.

Key Players In The Global Inhaled Antibiotics Market

Major companies operating in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Novartis AG, Bayer AG, Pfizer Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals.

Global Inhaled Antibiotics Market Trends and Insights

Major companies operating in the inhaled antibiotics market are focusing on innovative products such as Breyna to drive revenues in their market. Breyna is an inhalation aerosol that contains formoterol fumarate dihydrate and budesonide to manage and prevent symptoms such as wheezing, and shortness of breath brought on by asthma or persistent lung diseases. For instance, in July 2023, Viatris Inc. a US-based pharmaceutical company partnerd with Kindeva Drug Delivery L.P. a US-based company that specializes in drug delivery technologies to launch breyna. Breyna inhalation is a combination product that contains two medications, budesonide and formoterol. The drug is supplied as a metered-dose inhaler that combines budesonide with formoterol fumarate dihydrate as an inhalation aerosol. It comes in two strengths: 80mcg/4.5mcg and 160mcg/4.5mcg. The U.S. Food and Drug Administration (FDA) has approved Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol which is the first generic version of AstraZeneca's Symbicort.

What Are Latest Mergers And Acquisitions In The Inhaled Antibiotics Market?

In January 2024, Essential Pharma, a UK-based pharmaceutical company, acquired Colobreathe from Teva Laboratories UK Limited for an undisclosed amount. This acquisition marks Essential Pharma's entry into the rare disease sector, expanding its portfolio with treatments for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. Through this deal, the company aims to ensure continuous access to vital medicines across Europe. Teva Laboratories UK Limited is a UK-based manufacturer of inhaled antibiotics.

Regional Insights

North America was the largest region in the inhaled antibiotics market share in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Inhaled Antibiotics Market?

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inhaled Antibiotics Market Report 2026?

The inhaled antibiotics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.